Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Next Previous
Search
Trial Profile

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avutometinib (Primary) ; Defactinib (Primary)
  • Indications Adenocarcinoma; Ovarian cancer; Peritoneal cancer
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms RAMP 201
  • Sponsors Verastem Oncology

    • Most Recent Events

    • 20 Feb 2025 According to a Verastem Oncology media release, company announced multiple oral and poster presentations, including an oral presentation of additional analyses from this trial at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer, to be held on March 14-17 in Seattle, Washington. Verastem will also have an exhibition booth 622 at the meeting where it will be available to discuss its ongoing cancer research.
    • 23 Jan 2025 According to a Verastem Oncology media release, company will submit submit RAMP 201 primary analysis publication for NCCN consideration in H1 2025. Company will present additional analyses from the RAMP 201 trial at a medical meeting in Q1 2025.
    • 30 Dec 2024 According to a Verastem Oncology media release, the NDA, which was completed in Oct 2024, has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of Jun 30, 2025. In addition, the FDA has stated that it is not currently planning to hold an advisory committee meeting to discuss the application.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top